SCHEMBL668403

SCHEMBL668403

COc1cccc(CN2CCC(O)(c3ccc(F)c(Cl)c3)CC2)c1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.62
SIGMAR1 Q99720 1/20 0.54
HTR1D P28221 1/20 0.52
CCR3 P51677 1/20 0.52
OPRL1 P41146 4/20 0.51
DRD2 P14416 1/20 0.50
DRD3 P35462 1/20 0.50
KCNH2 Q12809 1/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
OPRM1 P35372 1/20 0.49
MAPT P10636 3/20 0.49
TSHR P16473 2/20 0.49
KDM4E B2RXH2 1/20 0.49
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL666461 0.92 ALDH1A1 (0.62) ALDH1A1SIGMAR1HTR1DCCR3OPRL1
SCHEMBL668316 0.90 ALDH1A1 (0.62) ALDH1A1SIGMAR1HTR1DCCR3OPRL1
SCHEMBL667773 0.90 ALDH1A1 (0.65) ALDH1A1SIGMAR1HTR1DCCR3OPRL1
SCHEMBL667229 0.88 CCR3 (0.68) ALDH1A1SIGMAR1HTR1DCCR3OPRL1
SCHEMBL666457 0.87 ALDH1A1 (0.70) ALDH1A1SIGMAR1HTR1DCCR3OPRL1
SCHEMBL667793 0.85 ALDH1A1 (0.61) ALDH1A1SIGMAR1HTR1DCCR3OPRL1
SCHEMBL667088 0.84 ALDH1A1 (0.57) ALDH1A1SIGMAR1HTR1DCCR3OPRL1
SCHEMBL4816046 0.82 ALDH1A1 (0.80) ALDH1A1SIGMAR1CCR3OPRL1DRD2
SCHEMBL664827 0.81 CCR3 (0.58) ALDH1A1SIGMAR1HTR1DCCR3OPRL1
Hydrochloric Acid SCHEMBL6288091 0.81 ALDH1A1 (0.78) ALDH1A1SIGMAR1CCR3OPRL1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045468-B2 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-06-02 US disclosed
EP-2606049-A2 2,5-METHANO-AND 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN Albany Molecular Research, Inc. (US) 2013-06-26 EP disclosed
US-20120046271-A1 2,5-Methano- and 2,5-Ethano-Tetrahydrobenzazepine Derivatives And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine, and Serotonin BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-23 US disclosed
WO-2012024397-A2 2,5-METHANO-AND 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2012-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046271-A1 2,5-Methano- and 2,5-Ethano-Tetrahydrobenzazepine Derivatives And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine, and Serotonin HTR2B, HTR1B, HTR5A ALDH1A1 970/4885SIGMAR1 97/4885HTR1D 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.